NCT00315211View on ClinicalTrials.gov

Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

June 30, 2007

Study Completion Date

November 8, 2007

Conditions
Mediastinal Neoplasms
Interventions
DRUG

Intravenous Topotecan

Topotecan 3 mg/m2 IV over 30 minutes on Days 1 and 8 every 21 days

DRUG

Intravenous Docetaxel

Docetaxel 30 mg/m2 IV over 60 minutes on Days 1 \& 8 of a 21 day cycle

Trial Locations (1)

44710

Aultman Hospital, Canton

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Aultman Health Foundation

OTHER